Climb Bio, Inc.
NASDAQ•CLYM
CEO: Dr. Aoife M. Brennan BAO, BCh, M.D., MB, MMSc
Sector: Healthcare
Industry: Biotechnology
Listing Date: 2021-08-10
Climb Bio, Inc., a biotechnology company, focuses on developing therapies for autoimmune-driven inflammatory diseases. It develops budoprutug, an anti-CD19 monoclonal antibody for various autoimmune diseases, including systemic lupus erythematosus and lupus nephritis, immune thrombocytopenia, and membranous nephropathy. The company was formerly known as Eliem Therapeutics, Inc. and changed its name to Climb Bio, Inc. in October 2024. Climb Bio, Inc. was incorporated in 2018 and is headquartered in Wilmington, Delaware.
Contact Information
PMB #117, 2801 Centerville Road, 1st Floor, Wilmington, DE, 19808-1609, United States
866-857-2596
Market Cap
$780.03M
P/E (TTM)
-14.8
24.5
Dividend Yield
--
52W High
$12.48
52W Low
$1.16
52W Range
Rank49Top 66.7%
3.2
F-Score
Modified Piotroski Analysis
Based on 6-year fundamentals
Weak • 3.2 / 9 points
Scoring Range (0-9)
8-9: Excellent Value
6-7: Strong Fundamentals
4-5: Average Quality
0-3: Weak Performance
Data Period: 2020-2025
Deep Research
Financials
Earnings Calls
Reports
News
Income Statement
Balance Sheet
Cash Flow Statement
Ratios
% Chg.
Income Statement | LTM |
|---|
No Data